Cable Viewer

Currently released so far... 12646 / 251,287

### Browse latest releases

2010/11 2010/12 2011/01 2011/02 2011/03 2011/04 2011/05
2010/11/28 2010/11/29 2010/11/30
2010/12/01 2010/12/02 2010/12/03 2010/12/04 2010/12/05 2010/12/06 2010/12/07 2010/12/08 2010/12/09 2010/12/10 2010/12/11 2010/12/12 2010/12/13 2010/12/14 2010/12/15 2010/12/16 2010/12/17 2010/12/18 2010/12/19 2010/12/20 2010/12/21 2010/12/22 2010/12/23 2010/12/24 2010/12/25 2010/12/26 2010/12/27 2010/12/28 2010/12/29 2010/12/30
2011/01/01 2011/01/02 2011/01/04 2011/01/05 2011/01/07 2011/01/09 2011/01/10 2011/01/11 2011/01/12 2011/01/13 2011/01/14 2011/01/15 2011/01/16 2011/01/17 2011/01/18 2011/01/19 2011/01/20 2011/01/21 2011/01/22 2011/01/23 2011/01/24 2011/01/25 2011/01/26 2011/01/27 2011/01/28 2011/01/29 2011/01/30 2011/01/31
2011/02/01 2011/02/02 2011/02/03 2011/02/04 2011/02/05 2011/02/06 2011/02/07 2011/02/08 2011/02/09 2011/02/10 2011/02/11 2011/02/12 2011/02/13 2011/02/14 2011/02/15 2011/02/16 2011/02/17 2011/02/18 2011/02/19 2011/02/20 2011/02/21 2011/02/22 2011/02/23 2011/02/24 2011/02/25 2011/02/26 2011/02/27 2011/02/28
2011/03/01 2011/03/02 2011/03/03 2011/03/04 2011/03/05 2011/03/06 2011/03/07 2011/03/08 2011/03/09 2011/03/10 2011/03/11 2011/03/13 2011/03/14 2011/03/15 2011/03/16 2011/03/17 2011/03/18 2011/03/19 2011/03/20 2011/03/21 2011/03/22 2011/03/23 2011/03/24 2011/03/25 2011/03/26 2011/03/27 2011/03/28 2011/03/29 2011/03/30 2011/03/31
2011/04/01 2011/04/02 2011/04/03 2011/04/04 2011/04/05 2011/04/06 2011/04/07 2011/04/08 2011/04/09 2011/04/10 2011/04/11 2011/04/12 2011/04/13 2011/04/14 2011/04/15 2011/04/16 2011/04/17 2011/04/18 2011/04/19 2011/04/20 2011/04/21 2011/04/22 2011/04/23 2011/04/24 2011/04/25 2011/04/26 2011/04/27 2011/04/28 2011/04/29 2011/04/30
2011/05/01 2011/05/02 2011/05/03 2011/05/04 2011/05/05 2011/05/06 2011/05/07 2011/05/08 2011/05/09 2011/05/10 2011/05/11 2011/05/12 2011/05/13 2011/05/14 2011/05/15 2011/05/16 2011/05/17

### Browse by creation date

66 72 73 75 79 85 86 87 88 89 90 91 92 93 94 96 97 00 01 02 03 04 05 06 07 08 09 10
1966/12
1972/02 1972/08
1973/04
1975/03
1979/08
1985/03 1985/05 1985/06
1986/05
1987/06
1988/01 1988/03 1988/07
1989/12
1990/01 1990/07 1990/08 1990/10
1991/05
1992/01 1992/03 1992/06 1992/09 1992/12
1993/01 1993/10
1994/12
1996/11
1997/06 1997/12
2000/05 2000/06 2000/09 2000/11
2001/02 2001/03 2001/06 2001/07 2001/09 2001/10 2001/11
2002/01 2002/02 2002/03 2002/04 2002/07 2002/08 2002/09 2002/11 2002/12
2003/01 2003/02 2003/03 2003/04 2003/05 2003/06 2003/07 2003/08 2003/09 2003/10 2003/11 2003/12
2004/01 2004/02 2004/03 2004/04 2004/05 2004/06 2004/07 2004/08 2004/09 2004/10 2004/11 2004/12
2005/01 2005/02 2005/03 2005/04 2005/05 2005/06 2005/07 2005/08 2005/09 2005/10 2005/11 2005/12
2006/01 2006/02 2006/03 2006/04 2006/05 2006/06 2006/07 2006/08 2006/09 2006/10 2006/11 2006/12
2007/01 2007/02 2007/03 2007/04 2007/05 2007/06 2007/07 2007/08 2007/09 2007/10 2007/11 2007/12
2008/01 2008/02 2008/03 2008/04 2008/05 2008/06 2008/07 2008/08 2008/09 2008/10 2008/11 2008/12
2009/01 2009/02 2009/03 2009/04 2009/05 2009/06 2009/07 2009/08 2009/09 2009/10 2009/11 2009/12
2010/01 2010/02

### Browse by origin

A B C D F G H I J K L M N O P Q R S T U V W Y Z
Embassy Athens Embassy Asuncion Embassy Astana Embassy Asmara Embassy Ashgabat Embassy Apia Embassy Ankara Embassy Amman Embassy Algiers Embassy Addis Ababa Embassy Accra Embassy Abuja Embassy Abu Dhabi Embassy Abidjan Consulate Auckland Consulate Amsterdam Consulate Adana American Institute Taiwan, Taipei
Embassy Bujumbura Embassy Buenos Aires Embassy Budapest Embassy Bucharest Embassy Brussels Embassy Bridgetown Embassy Bratislava Embassy Brasilia Embassy Bogota Embassy Bishkek Embassy Bern Embassy Berlin Embassy Belmopan Embassy Belgrade Embassy Beirut Embassy Beijing Embassy Banjul Embassy Bangkok Embassy Bandar Seri Begawan Embassy Bamako Embassy Baku Embassy Baghdad Consulate Barcelona
Embassy Copenhagen Embassy Conakry Embassy Colombo Embassy Chisinau Embassy Caracas Embassy Canberra Embassy Cairo Consulate Curacao Consulate Ciudad Juarez Consulate Chennai Consulate Casablanca Consulate Cape Town Consulate Calgary
Embassy Dushanbe Embassy Dublin Embassy Doha Embassy Djibouti Embassy Dili Embassy Dhaka Embassy Dar Es Salaam Embassy Damascus Embassy Dakar Consulate Dubai
Embassy Freetown Consulate Fukuoka
Embassy Guatemala Embassy Gaborone Consulate Guayaquil Consulate Guadalajara
Embassy Helsinki Embassy Harare Embassy Hanoi Consulate Ho Chi Minh City Consulate Hermosillo Consulate Hamilton Consulate Hamburg Consulate Halifax
Iran RPO Dubai Embassy Islamabad Consulate Istanbul
Embassy Jakarta Consulate Jerusalem Consulate Jeddah
Embassy Kyiv Embassy Kuwait Embassy Kuala Lumpur Embassy Kinshasa Embassy Kingston Embassy Kigali Embassy Khartoum Embassy Kathmandu Embassy Kampala Embassy Kabul Consulate Kolkata
Embassy Luxembourg Embassy Luanda Embassy London Embassy Ljubljana Embassy Lisbon Embassy Lima Embassy Lilongwe Embassy La Paz Consulate Lahore Consulate Lagos
Mission USOSCE Mission USNATO Mission UNESCO Embassy Muscat Embassy Moscow Embassy Montevideo Embassy Monrovia Embassy Minsk Embassy Mexico Embassy Mbabane Embassy Maputo Embassy Manila Embassy Manama Embassy Managua Embassy Malabo Embassy Madrid Consulate Munich Consulate Mumbai Consulate Montreal Consulate Monterrey Consulate Milan Consulate Melbourne
Embassy Nicosia Embassy Niamey Embassy New Delhi Embassy Ndjamena Embassy Nassau Embassy Nairobi Consulate Naples Consulate Naha
Embassy Ouagadougou Embassy Ottawa Embassy Oslo
Embassy Pristina Embassy Pretoria Embassy Prague Embassy Port Of Spain Embassy Port Louis Embassy Port Au Prince Embassy Phnom Penh Embassy Paris Embassy Paramaribo Embassy Panama Consulate Peshawar
Embassy Quito Consulate Quebec
REO Basrah Embassy Rome Embassy Riyadh Embassy Riga Embassy Reykjavik Embassy Rangoon Embassy Rabat Consulate Rio De Janeiro Consulate Recife
Secretary of State Embassy Suva Embassy Stockholm Embassy Sofia Embassy Skopje Embassy Singapore Embassy Seoul Embassy Sarajevo Embassy Santo Domingo Embassy Santiago Embassy Sanaa Embassy San Salvador Embassy San Jose Consulate Strasbourg Consulate St Petersburg Consulate Shenyang Consulate Shanghai Consulate Sapporo Consulate Sao Paulo
Embassy Tunis Embassy Tripoli Embassy Tokyo Embassy The Hague Embassy Tel Aviv Embassy Tehran Embassy Tegucigalpa Embassy Tbilisi Embassy Tashkent Embassy Tallinn Consulate Toronto Consulate Tijuana
USUN New York USEU Brussels US Office Almaty US Mission Geneva US Interests Section Havana US Delegation, Secretary UNVIE Embassy Ulaanbaatar
Embassy Vilnius Embassy Vienna Embassy Vatican Embassy Valletta Consulate Vladivostok Consulate Vancouver
Embassy Windhoek Embassy Wellington Embassy Warsaw
Embassy Yerevan Embassy Yaounde
Embassy Zagreb

### Browse by tag

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
AORC AF AU ASEC AMGT AS APER AR AEMR AG ARF AJ AA AINF APECO AODE ABLD AMG ATPDEA AE AMED AGAO AFIN AL ASUP ASECKFRDCVISKIRFPHUMSMIGEG AID ASCH AM AORL ASEAN APEC ADM AFSI AFSN ADCO ABUD AN AY AIT ACOA ASIG AADP AGR ANET ADPM AMCHAMS ATRN ALOW ACS APCS AFFAIRS ADANA AECL ACAO AORG AROC AO ACABQ AGMT AX AMEX AFGHANISTAN AZ AND ARM AQ ATFN AMBASSADOR ACBAQ AC AUC ASEX AER AVERY AGRICULTURE AFU
BR BTIO BY BO BA BU BL BN BM BF BEXP BK BG BB BTIU BBSR BRUSSELS BD BIDEN BE BH BILAT BC BT BP BX BMGT BWC
CS CA CH CD CO CE CU CVIS CASC CJAN CI CPAS CMGT CDG CIC CAC CBW CWC COUNTER CW CT CR CY CNARC CACM CG CB CM CV CIDA CLINTON CHR COE CIS CDC CONS CF CFED CODEL CBSA CEUDA COM CARSON COPUOS CIA CL CN CROS CAPC CTR CACS CONDOLEEZZA CICTE COUNTRY CBE CKGR CVR COUNTERTERRORISM CITEL CLEARANCE CARICOM CSW CITT CDB CJUS CTM CAN CLMT CBC
DA DJ DEA DR DEAX DHS DAO DCM DOD DOMESTIC DO DK DPRK DEPT DISENGAGEMENT DE DOE DTRA DS DEFENSE
EAID ECON EFIS ETRD EC ENRG EINV EFIN EAGR ETTC ECPS EINT EPET ES EIND EAIR EU EUN EG ELAB EWWT EMIN ECIN ESA ER ETRDEINVECINPGOVCS EAIG ET ETRO ELTN EI EN EUR EK EUMEM ENIV EPA ENGR EXTERNAL EUREM ELN EUC ENERG EZ ERD EFTA ETRC ETRN EINVECONSENVCSJA EEPET EUNCH ENVR ESENV ENNP ERNG ENVI ETRDECONWTOCS ECINECONCS EFINECONCS EXIM ELECTIONS ECA EINVEFIN ETC EAP ECONOMY EINN ECONOMIC EXBS ECUN ENGY ECONOMICS EIAR EINDETRD ECONEFIN EURN EDU ETRDEINVTINTCS ECIP EFIM EAIDS EREL EINVETC ECONCS ETRA
FI FJ FR FDA FBI FTAA FAO FAC FARC FTA FMLN FO FAS FOREIGN FM FREEDOM FISO FOR FINR FINANCE FOI
GG GM GOI GT GR GH GTIP GV GA GAERC GE GCC GOV GZ GY GANGS GERARD GTMO GL GF GAZA GLOBAL
HR HA HU HO HURI HILLARY HYMPSK HSTC HK HEBRON HUMOR HI HUMAN
IC IV IAEA IR IT IO IN IS IZ IMO IPR IWC ICAO ILO ID ICTY ICJ INMARSAT INDO IL IMF IRS IQ IA ICRC IDA IAHRC IBRD ISLAMISTS IDP IGAD ILC ITRA ICTR ITU IBET ITF INRA INRO INTELSAT IEFIN IRC IRAQI ITALY ISRAELI IIP ITPGOV ITALIAN INTERNAL INTERPOL IEA INRB INR IZPREL IRAJ IF ITPHUM ISRAEL IACI
JA JO JM JOSEPH JP JUS JOHNNIE JAMES JOHN
KBTR KPAO KOMC KCRM KDEM KHIV KBIO KTIA KMDR KNNP KSCA KTIP KWMN KIPR KCOR KRVC KFRD KPAL KWBG KE KTDB KUNR KSPR KJUS KGHG KAWC KCFE KGCC KOLY KSUM KACT KISL KTFN KFLU KSTH KMPI KHDP KS KHLS KSEP KMRS KID KN KU KAWK KSAC KCOM KAID KIRC KWMNCS KMCA KNEI KCRS KPKO KICC KIRF KPOA KV KDRG KSEO KVPR KTER KBCT KFIN KGIC KCIP KZ KG KWAC KRAD KPRP KTEX KNAR KPLS KPAK KSTC KFLO KSCI KIDE KO KOMS KHSA KSAF KPWR KVRP KENV KNSD KFRDCVISCMGTCASCKOCIASECPHUMSMIGEG KCGC KVIR KFSC KDDG KPRV KTBT KWMM KX KMFO KR KMOC KRIM KCRCM KBTS KOCI KGIT KNUP KPAONZ KNUC KNNPMNUC KERG KTLA KCSY KTRD KNPP KJUST KCMR KRCM KCFC KCHG KREL KFTFN KLIG KDEMAF KPAI KICA KFRDKIRFCVISCMGTKOCIASECPHUMSMIGEG KHUM KREC KSEC KPIN KESS KDEV KWWMN KOM KWNM KRFD KMIG KRGY KIFR
LH LY LE LI LG LO LA LU LTTE LAB LOG LT LABOR
MARR MOPS MASS MX MNUC MCAP MO MR MEPP MTCRE MAPP MEPN MZ MT ML MA MY MIL MD MASSMNUC MU MK MTCR MUCN MAS MEDIA MAR MC MI MQADHAFI MPOS MARAD MG MTRE MASC MW MRCRE MP MOPPS MTS MLS MILI MEPI MEETINGS MERCOSUR MCC MIK MAPS MV MILITARY MDC
NATO NZ NL NO NK NU NPT NI NG NEW NSF NA NPG NSG NE NSSP NS NDP NSC NAFTA NH NV NP NPA NSFO NT NW NASA NORAD NGO NR NATIONAL NIPP NZUS NC NRR NAR NATOPREL
OEXC OTRA OPRC OVIP OAS OECD OIIP OSCE OREP OPIC OFDP OMIG ODIP OVP OSCI OIC OIE OPDC ON OCII OPAD OBSP OFFICIALS OPCW OHUM OES OCS OTR OSAC OFDA
PGOV PREL PM PHUM PTER PINR PINS PREF PARM PL PK PU PBTS PBIO PHSA PE PO PROP PA PNAT POL PLN POLITICAL PARTIES PCUL PAK PGGV PAO PSA PGOVSMIGKCRMKWMNPHUMCVISKFRDCA PAS PGIV PHUMPREL PDOV PHUMPGOV PCI PTBS PEL PG POLITICS POLICY PINL POGOV POV PRAM PP PREO PAHO PBT PREFA PSI PAIGH POSTS PMIL PALESTINIAN PARMS PROG PTERE PRGOV PORG PS PGOF PKFK PSOE PEPR PPA PINT PMAR PRELP PINF PNG PFOR PUNE PGOVLO PHUMBA PSEPC PNR POLINT PGOVE PHALANAGE PARTY PDEM PECON PROV PGOC PY PHUH PF PRL PHUS
QA
RU RS RO RW RP RFE REGION REACTION REPORT RCMP RM RSO ROBERT RICE RSP RF ROOD RIGHTS RIGHTSPOLMIL RUPREL RELATIONS
SENV SU SCUL SOCI SNAR SL SW SMIG SP SY SA SHUM SZ SYRIA SF SR SO SPCE SARS SN SC SIPRS SI SYR SEVN SNARCS SH SAARC STEINBERG SG SCRS SENVKGHG SAN ST SIPDIS SNARIZ SNARN SSA SK SPCVIS SOFA SANC SWE SHI SEN
TW TU TBIO TSPL TPHY TRGY TC TT TSPA TINT TERRORISM TX TR TS TN TD TH TIP TNGD TI TZ TF THPY TP TBID TL TV TK TO TRSY TURKEY TFIN TAGS
UN UK UNSC UNGA US UNESCO UP UNHRC UNAUS USTR UNDP UNEP UNMIK UY UNCHR UNO UG UZ UNPUOS USEU UNDC UNICEF UV UNHCR UNCND UNCHC UNCSD USUN USOAS UNFCYP USNC UNIDROIT USPS USAID UE UNVIE UAE UNODC UNCHS UNFICYP UNDESCO UNC
VE VAT VZ VN VC VT VM VI VTPREL VTIZ VTEG
WMO WHO WHA WA WI WWARD WHTI WTRO WS WTO WTRQ WBG WMD WIPO WFP WZ WB WITH WEU
XK XF XY XG XB XV XR XA XZ XM XL XW XS XD XX XU XI XT XH XQ XE XTAG XC
YI YE YM YMCS
ZB ZI ZEALAND ZP ZR ZF ZK ZU ZO ZL ZOELLICK ZJ ZN ZA ZANU

### Browse by classification

CONFIDENTIAL CONFIDENTIAL//NOFORN SECRET SECRET//NOFORN UNCLASSIFIED UNCLASSIFIED//FOR OFFICIAL USE ONLY

### Community resources

Follow us on Twitter Check our Reddit Twitter this Digg this page Contact us on IRC

courage is contagious

### Viewing cable 06OTTAWA2021, POTENTIAL FOR IPR PROGRESS: CANADA'S PROPOSED

If you are new to these pages, please read an introduction on the structure of a cable as well as how to discuss them with others. See also the FAQs
Understanding cables
Every cable message consists of three parts:

- The top box shows each cables unique reference number, when and by whom it originally was sent, and what its initial classification was.
- The middle box contains the header information that is associated with the cable. It includes information about the receiver(s) as well as a general subject.
- The bottom box presents the body of the cable. The opening can contain a more specific subject, references to other cables (browse by origin to find them) or additional comment. This is followed by the main contents of the cable: a summary, a collection of specific topics and a comment section.

To understand the justification used for the classification of each cable, please use this WikiSource article as reference.
Discussing cables
If you find meaningful or important information in a cable, please link directly to its unique reference number. Linking to a specific paragraph in the body of a cable is also possible by copying the appropriate link (to be found at theparagraph symbol). Please mark messages for social networking services like Twitter with the hash tags #cablegate and a hash containing the reference ID e.g. #06OTTAWA2021.

Reference ID | Created | Released | Classification | Origin
--- | --- | --- | --- | ---
06OTTAWA2021 | 2006-06-29 19:57 | 2011-04-28 00:00 | UNCLASSIFIED//FOR OFFICIAL USE ONLY | Embassy Ottawa

`

    VZCZCXRO5122
    RR RUEHGA RUEHHA RUEHQU RUEHVC
    DE RUEHOT #2021/01 1801957
    ZNR UUUUU ZZH
    R 291957Z JUN 06
    FM AMEMBASSY OTTAWA
    TO RUEHC/SECSTATE WASHDC 3024
    INFO RUCNCAN/ALL CANADIAN POSTS COLLECTIVE
    RUCPDOC/DEPT OF COMMERCE WASHDC

` `

    UNCLAS SECTION 01 OF 02 OTTAWA 002021

    SIPDIS

    SENSITIVE
    SIPDIS

    STATE PASS TO USTR FOR GARDE, ESPINEL, CHANDLER
    STATE PASS TO USDOC FOR GWORD, JBOGER
    STATE PASS TO USPTO FOR MKEPLINGER

    E.O. 12958: N/A
    TAGS: KIPR ECON TBIO CA
    SUBJECT: POTENTIAL FOR IPR PROGRESS:  CANADA'S PROPOSED
    DATA PROTECTION REGULATIONS

    REF: A. OTTAWA 1701

         ¶B. OTTAWA 1317

    ¶1.  (SBU)  Summary:  The GOC has proposed a two-regulation
    package (significantly different from its 2004 proposal)
    consisting of data protection for the innovative
    pharmaceutical industries and "Patented Medicines (Notice of
    Compliance)" for the generic drug industries, a combination
    designed to force compromise between the two sectors.
    Although the innovative pharmaceutical industry organizations
    PhRMA and Rx&D have minor complaints which they hope to have
    addressed in the final regulations (the comment period ends
    July 17), in general the package seems to be a positive
    development for IPR protection in Canada.  In particular, the
    Data Protection regulation is designed to bring Canada into
    compliance with its international obligations to provide
    protection for proprietary data belonging to patent-holding
    companies, something that the Embassy has been encouraging.
    Assuming the proposed rules are finalized, industry observes
    believe that this will be a step forward for Canada's
    protection of IPR and will directly address one complaint
    from the last two Special 301 Reports on Canada.  End Summary.

    The Regulations
    ---------------

    ¶2.  (U)  (SBU)  The Patented Medicines (Notice of Compliance)
    or PMNOC regulation and, to a lesser extent, the Data
    Protection regulation are complex, and we would welcome
    insights from USG experts.  The data protection regulation
    can be found at
    canadagazette.gc.ca/partI/2006/20060617/html/ regle4-e.html
    The PMNOC regulation can be found at
    canadagazette.gc.ca/partI/2006/20060617/html/ regle6-e.html
    Our initial perusal and conversations with contacts have
    provided the following information.

    ¶3.  (SBU) The draft Data Protection regulation stipulates
    that a secondary manufacturer (usually a generic) cannot file
    a new drug submission on the basis of a direct or indirect
    comparison between the new drug and an innovative drug until
    six years after the first notice of compliance was issued to
    the innovator.  The submission will not be approved until at
    least eight years after the first notice of compliance was
    issued.  This data protection period of eight years compares
    favorably to the U.S. "five plus three" period.  (Comment:
    One observer joked to us that now Canada would have better
    data protection than the United States and that the
    innovative industry may start to use this as leverage to
    argue for better data protection in the United States.  End
    comment.)  Both the Canadian industry group Rx&D and PhRMA in
    the United States are preparing comments to submit to Health
    Canada.  From discussions with industry contacts, we believe
    the industry comments will focus on requests for
    clarification, particularly surrounding the transitional
    language that will determine how drug submissions already in
    the pipeline are treated.  A particular point which seems
    unclear to many observers (and of concern to the
    pharmaceutical industry) is paragraph (5) which states that
    the eight year protection period does not apply "if the
    innovative drug is not being marketed in Canada."  We expect
    that the final regulations will clarify how this will be
    applied.  However, the innovative industry's reaction to the
    data protection regulation is positive, with observers
    stating that this will not only bring Canada into compliance
    with its international obligations but will also make the
    country more competitive internationally.
    Qcountry more competitive internationally.

    ¶4.  (SBU)  The Patented Medicines (Notice of Compliance) or
    PMNOC regulation is the part of the package designed to keep
    the generic companies in the deal.  The PMNOC regulation is
    more complex than the data protection regulation, but in
    general it is intended to limit innovative drug companies'
    ability to "evergreen" drug patents, or renew patents based
    on small changes to a drug.  The PMNOC regulation attempts to
    address the unintended consequences of unclear language in
    previous regulation which required court interpretation;
    these include the "possibility that an innovator company may
    delay generic market entry by listing new and sometimes
    irrelevant patents on the basis of minor product revisions."
    In what seems to be a valuable victory for the innovative
    drug industry, however, the PMNOC's Regulatory Impact
    Assessment Statement states that dosage form patents (patents
    that focus on the form of the drug, not its chemical
    composition) deserve "special protection provided by the
    PM(NOC) regulations," adding that this is "particularly true

    OTTAWA 00002021  002 OF 002

    in the case of biologic drugs where effective administration
    of the medicinal ingredient is often dependent on the
    development of new and innovative delivery mechanisms."  The
    generic industry in Canada has not made any public statement
    on the draft regulations, although they will probably submit
    formal comments.  Our contacts also tell us that the generics
    are trying to arrange for meetings with relevant officials
    and members of parliament before the comment period ends on
    July 17.

    GOC Officials' Perspective
    ---------------------------

    ¶5.  (SBU) Our GOC contacts seem confident that these
    regulations will be finalized, with very few changes, in as
    short a period as is possible under Canada's regulatory
    process.  They describe the regulations as fair and balanced,
    and they suggest that neither the innovative nor the generic
    industry should be surprised by the regulations' content.  In
    general, this is what we are hearing from industry contacts
    as well, although industry contacts hesitate to describe
    themselves as happy with the regulations and insist that
    certain changes need to be made.  Any rhetoric about pushing
    for 10 years of data protection such as in Europe seems to be
    more a bargaining tool than an actual goal.  GOC officials
    are aware that both industries, but particularly the
    innovative industry, are eager for a package to be finalized
    and are willing to accept the compromises inherent in these
    proposed regulations.

    Domestic Political Context
    --------------------------

    ¶6.  (SBU) The current Conservative government has been more
    receptive to U.S. concerns about intellectual property
    rights, and domestically the Conservative party is less
    beholden to the generic industry, which is predominantly
    based in the greater Toronto area, a Liberal stronghold.
    (Comment:  a recent bit of much-hyped campaign scandal
    involved questionable donations to a Toronto-area Liberal
    MP--totalling C$54,000--from Apotex Inc's top two executives,
    their wives and six children.  Apotex is Canada's largest
    generic drug company.  End comment.)  The innovative drug
    companies, on the other hand, are primarily based in Quebec,
    where the Conservatives are very interested in picking up
    additional seats.  In general, this suggests that the
    generics industry, which is thought to be responsible for
    delaying progress on the 2004 proposal of the first version
    of these regulations, will not be able to delay progress on
    the new draft regulations.  The most optimistic timeframe for
    final regulations is probably the end of 2006.  As with our
    other IPR goal of amendments to the copyright act, much will
    hinge on whether another election is called in the meantime.
    An election before finalization of the regulations would at
    the very least delay them regulations and could result in yet
    another redraft.

    Visit Canada's Classified Web Site at
    http://www.state.sgov.gov/p/wha/ottawa

    WILKINS

`